Avid Bioservices Inc. Stock News

-- Recorded Second Quarter Revenue of $26.1 Million -- -- Initiated Strategic Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy --

Avid Bioservices, Inc.'s (CDMO) CEO Nick Green on Q2 2022 Results - Earnings Call Transcript

Avid Bioservices (NASDAQ:CDMO) reported its Q2 earnings results on Tuesday, December 7, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

On December 7, Avid Bioservices will release figures for Q2. Wall Street analysts are expecting earnings per share of $0.025. Go here to watch Avid Bioservices stock price in real-time ahead of earnings. Avid

Avid Bioservices (NASDAQ:CDMO) is set to give its latest quarterly earnings report on Tuesday, 2021-12-07. Here's what investors need to know before the announcement.

Zacks Investment Research lowered shares of Avid Bioservices (NASDAQ:CDMO) from a hold rating to a sell rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. []

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

The Cooper Companies (COO) delivered earnings and revenue surprises of -2.67% and 1.52%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices (NASDAQ:CDMO) is scheduled to release its earnings data after the market closes on Tuesday, December 7th. Analysts expect Avid Bioservices to post earnings of $0.02 per share for the quarter. Avid Bioservices (NASDAQ:CDMO) last posted its earnings results on Tuesday, September 7th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, []

TUSTIN, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2022 on December 7, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid''s senior management will discuss financial results for the first quarter and review recent corporate developments.

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEW YORK , Nov. 23, 2021 /PRNewswire/ -- As per Persistence Market Research''s latest industry analysis, the global antibodies contract manufacturing market was valued at 3.87 Bn in 2020, and is expected to exhibit a high CAGR of close to 13% over the forecast period (2021-2031). Rising prevalence of cancer and infectious diseases is creating rapid development and commercialization need for biopharmaceutical therapeutics. Ultimately, rise in the prevalence of both conditions is expected to drive the need for biologics. With advancements in contract solutions, leading CDMOs are focusing on the expansion of their integrated capabilities from molecule-to-finished product. The trend is significant as the acceleration of development and speed to market is becoming more crucial for biopharmaceutical and biologics developers. Owing to their high specificity and favorable safety profile associated with antibodies, contract manufacturing outsourcing presently comprises the largest class of biologics in the business, owing to legacy challenges related to the development and manufacturing of biologics.